Last deal

$165M

Amount

Post-IPO Equity

Stage

05.12.2022

Date

3

all rounds

$546.7M

Total amount

date founded

Financing round

General

About Company
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for cancer and other major diseases.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Karyopharm

founded date

01.01.2008

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company focuses on developing small molecule drugs that target critical pathways in cancer, inflammation, and cell proliferation by modulating the nuclear pore complex machinery. Karyopharm uses a unique technology platform to identify novel small molecules, optimize them into clinical candidates, and evaluate them in subsequent human clinical studies. Their lead compound, XPOVIO (selinexor), received accelerated approval from the FDA in 2019 and 2020 as a treatment for heavily pretreated multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma, respectively. Karyopharm also has several investigational programs in clinical or preclinical development, with their Selective Inhibitor of Nuclear Export (SINE) compounds showing biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Raptor Pharmaceuticals

Raptor Pharmaceuticals

Raptor is a NASDAQ-listed biopharmaceutical company developing life-altering therapeutics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Novato, CA, USA

total rounds

5

total raised

$222.89M
Auspex Pharmaceuticals

Auspex Pharmaceuticals

Auspex Pharmaceuticals develops therapeutics for depressive disorders and orphan diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

La Jolla, San Diego, CA, USA

total rounds

10

total raised

$123.82M
Idera Pharmaceuticals

Idera Pharmaceuticals

Idera Pharmaceuticals develops DNA- and RNA-based drugs for various diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Cambridge, MA, USA

total rounds

4

total raised

$74.5M
Addex Therapeutics

Addex Therapeutics

Addex Therapeutics develops and sells small molecule drugs for neurological disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Plan-les-Ouates, Switzerland

total rounds

20

total raised

$200.78M

Financials

Funding Rounds
8
3

Number of Funding Rounds

$546.7M

Money Raised

Their latest funding was raised on 05.12.2022. Their latest investor HealthCor Partners. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
06.03.2020
$172.5M
30.06.2014
$111M
Avidity Partners

Avidity Partners

Avidity Partners is an investment management firm that offers financial services.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Finance

count Of Investments

51

count Of Exists

1
Co-Investors
Investors
14
5

Number of lead investors

14

Number of investors

Investor 
Lead 
Round 
Partners 
No
Post-IPO Equity
No
Post-IPO Equity
No
Post-IPO Equity
HealthCor Partners

HealthCor Partners

HealthCor Partners is a registered investment advisor focused on private equity investments in the healthcare and life sciences industry.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Charleston, SC, USA

count Of Investments

22

count Of Exists

7
Heights Capital Management

Heights Capital Management

Heights Capital Management, Inc. is a private equity firm specializing in private investments in public equity in emerging growth companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

San Francisco, CA, USA

count Of Investments

21

count Of Exists

8

Armistice Capital

Armistice Capital is a global hedge fund focused on healthcare and consumer sectors.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Health Care, Financial Services

count Of Investments

25

People

Founders
3
Michael Christiano
Michael Christiano

Michael Christiano

Michael Christiano is the Chief Business Officer at the Broad Institute of MIT and Harvard. Michael Christiano attended Cornell University.

current job

Broad Institute
Broad Institute

organization founded

1

Michael Christiano

Ronald A. DePinho
Ronald A. DePinho

Ronald A. DePinho

Ronald DePinho is the Co-Founder & Chairman of the Scientific Advisory Board at Nirogy Therapeutics.

current job

AVEO Oncology
AVEO Oncology

organization founded

7

Ronald A. DePinho

Sharon Shacham
Sharon Shacham

Sharon Shacham

Dr. Shacham founded Karyopharm in 2008 and has served as our Chief Scientific Officer and President of Research and Development since December 2012, as our Chief Scientific Officer and Head of Research and Development from October 2010 to December 2012 and as our President and Chief Executive Officer from October 2010 to January 2011. Dr. Shacham has led our scientific progress since inception. Prior to joining Karyopharm, from 2000 to April 2009, she was Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., which underwent liquidation proceedings in 2009, and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc. which merged into Epix Pharmaceuticals in 2006, where she led the company’s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials. Dr. Shacham received her B.Sc. in Chemistry, Ph.D. and M.B.A. from Tel Aviv University.

current job

Karyopharm Therapeutics
Karyopharm Therapeutics

organization founded

1

Sharon Shacham

Employee Profiles
94

Sohanya Cheng

SVP Sales & Chief Commercial Officer

Ashley Mccarron

Director and counsel contracts management

Aileen Waters

Associate director, investigational product quality, karyopharm

Kate Procaccini

Director, marketing operations

Tanya Lewis

Executive vice president, chief regulatory and quality officer

Rachel Hansard

Vice president of marketing and market insights

Paula Larson

Associate director, accounting and reporting

Christina Hanson

Director, contracts management

Activity

Recent News
24
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month